We’re not out of the woods yet, but the major indices are turning green again and psychedelics, recently a relative investment pariah, are getting some love from investors. The…
Health Science
Filament Health (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. Cybin Therapeutics…
I remember back in my high school history days. When I studied the cold war, I learned that the Soviet Union had some of the most fertile land in…
Sector Summary The medical sector is a doozy. From cancer to cardiovascular diseases, areas of high unmet medical need are appearing faster than they can be dealt with. According…
Environmental, Social and Governance (ESG) focused investment is a relatively new accepted method for socially conscious investors to allocate their investment capital in public/private companies that align with their…
Does anyone get nervous when thinking about technology? Maybe I’ve read too much dystopian sci-fi, or maybe it’s the fact that I’ve been figuratively steeped in academic science and…
Algernon Pharmaceuticals (AGN.C) filed a combined clinical trials of investigational medicinal products and ethics approval application with the United Kingdom Medicines and Healthcare Products Regulatory Agency for its planned…
Spruce Biosciences Inc. (SPRB.Q) is a late-stage biopharmaceutical company developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical needs. The Company is credited for developing its…
An Insatiable Disease Cancer is a grim disease, feeding off numerous sources including tobacco, infections, environmental pollution, occupational carcinogens, and radiation, among others. Whether directly or indirectly, everyone has…
Perimeter Medical Imaging (PINK.V) has had quite the recent few months. The cherry on top was Chamath Palihapitaya’s Social Capital investment of $43.4 Million CAD. The fund is known…